PCI Biotech
Ronny Skuggedal is currently the CEO of PCI Biotech Holding ASA. Prior to this role, Ronny served as the CFO of the same company, where Ronny was responsible for finance, accounting, and investor relations. Ronny started their career at PricewaterhouseCoopers AS as an Associate and worked their way up to Director before leaving the company in September 2013. Ronny holds a Master in Professional Accountancy from BI Norwegian Business School.
This person is not in any offices
PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAC (nucleic acid therapeutics delivery).